Showing 4071-4080 of 5957 results for "".
- Sylentis Fails Phase 3 Trial of RNAi-based Drug Candidate for Dry Eye Associated with Sjögren's Syndromehttps://modernod.com/news/sylentis-fails-phase-3-trial-of-rnai-based-drug-candidate-for-dry-eye-associated-with-sjogrens-syndrome/2482110/Sylentis, a subsidiary of Spain-based PharmaMar, announced that its phase 3 SYL10111_V (RNAi-based tivanisiran) clinical trial for the treatment of dry eye disease associated with Sjögren’s syndrome did not meet its primary endpoint—the signs and symptoms of DED. T
- Adverum Announces Positive Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-positive-preliminary-efficacy-and-safety-data-from-luna-phase-2-trial-of-ixo-vec-in-patients-with-wet-amd/2482107/Adverum Biotechnologies announced preliminary safety and efficacy data from the ongoing LUNA phase 2 trial in patients with wet age-related macular degeneration (AMD). These data are being presented by Arshad Khanani, MD, today at the 47th Annual Meeting of the Macula Society. The presentation, t
- Shamir Launches Spark 4W Digital Electro-Optic Measurement Systemhttps://modernod.com/news/shamir-launches-spark-4w-digital-electro-optic-measurement-system/2482101/Shamir announced the launch of the Spark 4W, a digital electro-optic measurement system based on 3D stereo vision technology and artificial intelligence (AI) elements. Shamir Spark 4W is designed to enable eye care professionals (ECPs) to obtain precise and automatic meas
- 4D Molecular Therapeutics' Gene Therapy Maintains Stable Visual Acuity in Wet AMD Patients in Phase 2 Studyhttps://modernod.com/news/new-data-shows-4d-molecular-therapeutics-gene-therapy-cuts-eylea-use-in-wet-amd-patients/2482097/4D Molecular Therapeutics announced positive interim data from the phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (AMD) patients with severe disease activity and a high treatment burden. Data presented at the Angiogenesis, Exudat
- Aviceda Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for GAhttps://modernod.com/news/aviceda-therapeutics-announces-first-patient-dosed-in-part-2-of-the-phase-23-siglec-trial-assessing-avd-104-for-ga/2482092/Aviceda Therapeutics announced it has dosed the first patient in part 2 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “Based on the efficacy and safety we saw in part 1, we moved rapidly to i
- EuroEyes Group Wins SMILE Refractive Laser Eye Surgery Awardhttps://modernod.com/news/euroeyes-group-wins-smile-refractive-laser-eye-surgery-award/2482087/LEC London announced that its parent company EuroEyes Clinic Group, has won the SMILE Laser Operations Award for conducting the highest number of SMILE (Small Incision Lenticule Extraction) laser operations in Europe last year (2023). EuroEyes performed a total of 9,550 SMILE operations
- Ascendis Pharma Forms New Ophthalmology Company Eyconishttps://modernod.com/news/ascendis-pharma-forms-new-ophthalmology-company-eyconis/2482086/Ascendis Pharma A/S announced the formation and launch of Eyconis, a company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally. The new company was developed with Frazier Life Sciences, as well as an investor syndicate that includes RA Capital Man
- Mass Eye and Ear: Retinal Imaging and Genetics Data Used to Predict Future Disease Riskhttps://modernod.com/news/mass-eye-and-ear-retinal-imaging-and-genetics-data-used-to-predict-future-disease-risk/2482082/In a new study published in Science Translational Medicine, physician-researchers from Mass Eye and Ear, and the Broad Institute of MIT and Harvard, combined retinal imaging, genetics and big data to estimate how likely a person is to develop eye and systemic diseases in the future.
- Outlook Therapeutics Receives FDA Agreement Under SPA for 90 Day Noninferiority Study, NORSE EIGHThttps://modernod.com/news/outlook-therapeutics-receives-fda-agreement-under-special-protocol-assessment-for-90-day-noninferiority-study-norse-eight/2482077/Outlook Therapeutics announced that it has received written agreement from the FDA under a special protocol assessment (SPA) for the NORSE EIGHT clinical trial protocol evaluating ONS-5010 in wet age-related macular degeneration (AMD) subjects. Additionally, Outlook Therapeutics announc
- Rayner's RayOne EMV Receives Health Canada Approvalhttps://modernod.com/news/rayners-rayone-emv-receives-health-canada-approval/2482076/Rayner announced the approval of RayOne EMV by Health Canada. Developed in collaboration with Professor Graham Barrett, RayOne EMV is the only patented aspheric IOL that induces controlled positive spherical aberration to slightly extend the depth of focus, according to Rayner [1].